Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LRRTM4 antisense RNA 1 (LRRTM4-AS1)
- Target
- LRRTM4-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
LRRTM4 antisense RNA 1 (LRRTM4-AS1) is a long non-coding RNA transcribed from the opposite strand to the LRRTM4 gene. It is nuclear localized and acts in cis to regulate the transcription of LRRTM4 by binding to its promoter region. LRRTM4-AS1 is highly expressed in colorectal cancer and functions as a tumor promoter by enhancing LRRTM4 expression, promoting cell cycle progression, proliferation, migration, invasion, and inhibiting apoptosis. High LRRTM4-AS1 expression correlates with poor prognosis in colorectal cancer, making it a potential therapeutic target and biomarker. There is no evidence of direct drug targeting or mechanisms beyond RNA interference and genetic manipulation[2][4][10].
- Other names
- LRRTM4-AS1LRRTM4 antisense RNA 1LOC101927907
02
Mechanism of action
Not applicable: No drugs directly target this RNA. However, knockdown or inhibition of LRRTM4-AS1 has been shown experimentally to suppress colorectal cancer cell proliferation and induce apoptosis[2].
03
Biological functions
Transcriptional regulation (in cis, by binding the LRRTM4 promoter)Modulation of chromatin structure and gene expressionPromotion of cell proliferationInhibition of apoptosisEnhancement of cell migration and invasion (Epithelial-mesenchymal transition, EMT)
04
Disease associations
Cancer (specifically colorectal cancer)Potential biomarker predictive of poor prognosis in colorectal cancer (high expression is associated with poor survival)
05
Safety considerations
None specifically reported. Typical challenges related to lncRNA targeting include off-target effects and delivery/uptake in vivo.
06
Biomarkers
LRRTM4-AS1 expression (prognostic biomarker for colorectal cancer)
Beyond the preview
Go deeper on LRRTM4 antisense RNA 1 (LRRTM4-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LRRTM4 antisense RNA 1 (LRRTM4-AS1).